RE:Article posted on CEO Rockerfeller Foundation White PaperGreat article. I have copied some of the points relative to Sona COVID-19 tests.
The full article should be read.
Thanks Shoosh22
The lack of accepted gold standards and high-quality validation sample panels has been a limiting factor to date. The availability of validation sample sets from FDA and NCI is a major step in the right direction. However, the establishment of a nationally accepted gold standard assay will have a substantial impact on the evaluation of existing and future tests.
If simple point-of-care devices are employed, testing can be conducted at the site of presentation. Self-testing has been reported, but so far test performance has been problematic.
Surprisingly, many appeared as early as January 2020. Reports suggest that many of these very early tests were relabeled SARS-CoV-1 tests. Over the last several weeks, the FDA has removed more than 50 immunoassays from the market due to performance and other concerns.
Near-term improvements: A number of new point of care immunoassays are under development that are likely to provide higher performance than the first wave of products. If successful, they will be well received. There is a focus on very high specificity.